Scienmag
SEPTEMBER 27, 2020
New study based on the early versus late intervention trial with estradiol data confirms benefit of hormone therapy in reducing multiple biomarkers of inflammation CLEVELAND, Ohio (September 28, 2020)–As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health (..)
Scienmag
APRIL 19, 2021
Hypertension Journal report DALLAS, April 19, 2021 — Gender-affirming hormone therapy (GAHT) was associated with blood pressure changes in both transgender men and women, according to new research published today in Hypertension, an American Heart Association journal.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Scienmag
SEPTEMBER 27, 2020
Yale physician to discuss the most promising developments in estrogen therapy, including new fetal estrogens, during the 2020 NAMS Virtual Annual Meeting Pre-Meeting Symposium CLEVELAND, Ohio (September 28, 2020)–Hormone therapy remains the best proven method for managing menopause symptoms such as hot flashes.
Scienmag
AUGUST 11, 2020
New study identifies frequency of hormone therapy use and predictors of its use in women who underwent preventive oophorectomy as a result of carrying the BRCA gene CLEVELAND, Ohio (August 12, 2020)–Removal of the ovaries before natural menopause (surgical menopause) often exacerbates menopause symptoms and places women at increased risk for (..)
Scienmag
APRIL 26, 2021
American Heart Association Scientific Statement DALLAS, April 26, 2021 — The hormonal therapies used to treat many breast and prostate cancers raise the risk of a heart attack and stroke, and patients should be monitored regularly and receive treatment to reduce risk and detect problems as they occur, according to a new American Heart Association (..)
The Pharma Data
OCTOBER 22, 2020
That means a woman already predisposed to have a dissection is more likely to have one during pregnancy, possibly due to hormones and changes to the body during pregnancy and postpartum. Melinda Davis, a cardio-obstetrics expert at University of Michigan Medicine, said in a university news release. 14 in the journal JAMA Cardiology.
Delveinsight
DECEMBER 29, 2020
Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist. To overcome this, Glucagon, a hormone in the body, helps the liver to quickly increase blood sugar levels. mg and norethindrone acetate (0.5 mg) in the US and Canada.
Expert insights. Personalized for you.
46 
Let's personalize your content